Results 251 to 260 of about 166,279 (314)
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Best Practice & Research Clinical Obstetrics & Gynaecology, 2023
Expectant management of a cesarean scar pregnancy (CSP) is associated with a high risk of severe maternal morbidity. Therefore, most experts recommend immediate termination after the diagnosis of a CSP. However, there is no consensus about the optimal management of a CSP in terms of efficacy, safety, and preservation of future fertility.
NOEL, Laure, Chantraine, Frédéric
openaire +2 more sources
Expectant management of a cesarean scar pregnancy (CSP) is associated with a high risk of severe maternal morbidity. Therefore, most experts recommend immediate termination after the diagnosis of a CSP. However, there is no consensus about the optimal management of a CSP in terms of efficacy, safety, and preservation of future fertility.
NOEL, Laure, Chantraine, Frédéric
openaire +2 more sources
Pharmacokinetics of Methotrexate and 7-Hydroxy-Methotrexate After Methotrexate Infusions
Cancer Drug Delivery, 1987Methotrexate was administered by IV infusion, 2g (1.19 +/- 0.05 g/m2) over 24 hours, to a homogeneous group of patients undergoing treatment for breast cancer. Three courses were given at three week intervals. Methotrexate and 7-hydroxy-methotrexate plasma and urine pharmacokinetics were investigated. The average terminal half-lives of methotrexate and
P, Bore +4 more
openaire +2 more sources
Home Healthcare Now, 2015
The purpose of this article is to educate healthcare professionals about the many uses of the drug Methotrexate. Information regarding dosing, action, contraindications, adverse effects, drug interactions, as well as tips for patient education are included.
openaire +3 more sources
The purpose of this article is to educate healthcare professionals about the many uses of the drug Methotrexate. Information regarding dosing, action, contraindications, adverse effects, drug interactions, as well as tips for patient education are included.
openaire +3 more sources
Pharmacokinetics of methotrexate
Clinical Pharmacology & Therapeutics, 1973The pharmacokinetics of SH‐methotrexate were studied in 22 patients with malignancies. Following the intravenous administration of 30 mg methotrexate (Mtx) per square meter, the plasma disappearance was triphasic with half‐lifes of 0.7.5 ± 0.11,3.49 ± 0 . .55, and 26.99 ± 4.44 hours, respectively.
D H, Huffman +3 more
openaire +2 more sources
Clinical and Experimental Dermatology, 1996
Methotrexate is an effective antipsoriatic agent and has been widely used to treat severe psoriasis since the 1960s. It is especially useful in acute generalized pustular psoriasis, psoriatic erythroderma, psoriatic arthritis and for extensive chronic plaque psoriasis in patients who are inadequately controlled by topical therapy alone.
M J, Boffa, R J, Chalmers
openaire +2 more sources
Methotrexate is an effective antipsoriatic agent and has been widely used to treat severe psoriasis since the 1960s. It is especially useful in acute generalized pustular psoriasis, psoriatic erythroderma, psoriatic arthritis and for extensive chronic plaque psoriasis in patients who are inadequately controlled by topical therapy alone.
M J, Boffa, R J, Chalmers
openaire +2 more sources
The Journal of Dermatology, 1999
AbstractMethotrexate (MTX) nodulosis in patients with rheumatoid arthritis treated with MTX has become a well recognized phenomenon. It has not been described in patients receiving MTX for treatment of other diseases, e.g., dermatological or malignant diseases. Recently, MTX nodulosis was described in a patient with psoriasis and arthritis.
K A, Jang +5 more
openaire +2 more sources
AbstractMethotrexate (MTX) nodulosis in patients with rheumatoid arthritis treated with MTX has become a well recognized phenomenon. It has not been described in patients receiving MTX for treatment of other diseases, e.g., dermatological or malignant diseases. Recently, MTX nodulosis was described in a patient with psoriasis and arthritis.
K A, Jang +5 more
openaire +2 more sources
Journal of Allergy and Clinical Immunology, 1991
Recent trials of low-dosage methotrexate in chronic steroid-dependent asthma have engendered considerable interest and debate. It is still too early to say whether the variable sterold-sparlng effects In the reports to date will be found In other controlled studies underway.
openaire +2 more sources
Recent trials of low-dosage methotrexate in chronic steroid-dependent asthma have engendered considerable interest and debate. It is still too early to say whether the variable sterold-sparlng effects In the reports to date will be found In other controlled studies underway.
openaire +2 more sources